- Home
- GERN vs OIG Comparison
GERN vs OIG Comparison
Compare GERN & OIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GERN | OIG |
|---|---|---|
| Founded | 1990 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | GERN | OIG |
|---|---|---|
| Price | $1.31 | $10.38 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.17 | N/A |
| AVG Volume (30 Days) | ★ 8.8M | 907.5K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,065,000.00 | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $10.81 |
| 52 Week High | $2.01 | $12.06 |
Technical Indicators
Market Signals| Indicator | GERN | OIG |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | N/A |
| Support Level | $1.24 | N/A |
| Resistance Level | $1.32 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 10.00 | 0.00 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.